tbuckley/cabot-search huggingface dataset:
Abstract 10970: Simultaneous Atrial and Ventricular Pacing Can Separate Atrial Tachycardia from Atrioventricular Nodal Reentrant Tachycardia
Authors: Samir Saba, Sanjoy Bhattarchaya, Mezu Ure, Eathar Razak, G Stuart Mendenhall, Evan Adelstein, Sandeep Jain, William Barrington, David Schwartzman
Journal: Circulation (2010)

Background: Identifying the mechanism of supraventricular tachycardia (SVT) can often be challenging. We investigated the role of simultaneous atrial and ventricular (A+V) pacing in discriminating ...
Highlights of the 2005 Scientific Sessions of the American Society of Nuclear Cardiology
Authors: Jeroen J. Bax, Brian G. Abbott, Daniel S. Berman, Ernest V. Garcia, Robert S. Gropler, Robert C. Hendel, Diwakar Jain, Jennifer H. Mieres, Raymond R. Russell, Leslee J. Shaw, James E. Udelson, Frans J. Th. Wackers
Journal: Journal of the American College of Cardiology (2006)
Combinations of cytokines fused to antibodies as therapeutic agents against different peritoneal HER2/neu expressing tumors
Authors: Gustavo Helguera, Jose A. Rodriguez, Manuel L. Penichet
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

642 

We have previously generated anti-human HER2/neu humanized IgG3 fused to IL-2, IL-12 or GM-CSF [mono-functional fusion proteins (mono-AbFPs)] or fused to IL-2 and IL-12 or IL-12 and GM-CSF [bi-functional fusion proteins (bi-AbFPs)]. These AbFPs retained cytokine and antigen binding activities. In addition, bi-AbFPs and combinations of mono-AbFPs have proven to be strong adjuvants of HER2/neu protein vaccination, eliciting better anti-tumor protection than mono-AbFPs alone. We have now further characterized the AbFPs and determined the heparin-binding activity of the fused cytokines, their ability to trigger IFN-gamma secretion and NK activation, as well as their direct anti-tumor efficacy. Flow cytometry revealed heparin-binding activity in the AbFPs containing IL-12 and IL-2, although this activity seems to be decreased in the bi-AbFPs. However, both bi-AbFPs retained the capacity to stimulate IL-12 dependent IFN-_amma secretion in the NK cell line KY-1, and IL-12/IL-2 bi-AbFP induced NK activity in splenocytes. The anti-tumor effectiveness of bi-AbFPs and mono-AbFP combinations was studied in mice challenged i.p. with three different human HER2/neu murine syngeneic models (D2F2/E2, CT26-HER2/neu, and MC38-HER2/neu). Although a significant variability in the profile of anti-tumor response was observed in the different tumor models, the best response was obtained in the combination of IL-12 and GM-CSF mono-AbFPs. In contrast, bi-AbFPs protected less than the combination of mono-AbFPs, and in some models even less than mono-AbFPs alone. However, in all cases most of long-term survivors showed protection after s.c. rechallenge with the tumors and later with the parental tumors not expressing HER2/neu. These results demonstrate that, although the pattern of protection is tumor model dependent, treatments with AbFPs can effectively generate high levels of protection against peritoneal tumors expressing HER2/neu, which may be relevant in patients with primary or metastatic peritoneal carcinomatosis that may be observed in ovarian, colon, stomach, bladder, breast, and pancreatic cancers.
Deletional mutant EGFR detected in circulating tumor-derived DNA from lung cancer patients treated with gefitinib.
Authors: Hideharu Kimura, Hisao Fukumoto, Sarah Park, Hideo Kunito, Tomohide Tamura, Kazuo Kasahara, Kazuto Nishio
Journal: Cancer Research (2005)

479   NSCLC cells carrying the somatic mutation of epidermal growth factor receptor (EGFR) have been shown to be hyper-responsive to the EGFR-specific tyrosine kinase inhibitor gefitinib. The short, in-frame, 15-bp deletion of EGFR (E746_A750del) can be observed in serum DNA and may serve as a noninvasive source of information regarding the genotype of the original tumor cells that could influence treatment and the ability to predict a patient’s response to gefitinib. We identified the E746_A750del in tumor cells isolated from the serum of Japanese NSCLC patients treated with first-line gefitinib (Iressa ® ) monotherapy. Both the E746_A750del (10/27) and the wild-type EGFR (22/27) were detected in the pretreatment samples. No correlations were seen between the presence of the E746_A750del in the pretreatment samples and the response or the gender. When the presence of E746_A750del in pre-treatment and post-treatment samples was compared, E746_A750del was significantly more frequently observed in the post-treatment samples from patients with a partial response or stable disease than in those from patients with a progressive disease (p
Targeted therapy of gynecological tumors with cytotoxic peptide analogs
Authors: Jörg B. Engel, Michael Teifel, Andrew V. Schally
Journal: Cancer Research (2006)

3082  A high percentage of gynecological tumors express receptors for luteinizing hormone releasing hormone (LHRH), bombesin and somatostatin. 2-Pyrrolinodoxorubicin, a highly potent derivative of doxorubicin, was coupled to peptide analogs of these hormones. These hybrid molecules can be used for the targeted therapy of gynecological cancers. Human breast (MX-1, MDA-MB-231, MDA-MB-435, MDA-MB-468, DU-4475, endometrial (HEC-1-A, RL-95-2, AN3CA) and ovarian cancer (ES-2, UCI-107, OV-1063) cell lines were tested for the presence of LHRH, bombesin and somatostatin recepetors. Anti-tumor activity and toxicity of targeted cytotoxic analogs of LHRH (AN-207), bombesin (AN-215) and somatostatin (AN-238) was evaluated in nude mouse models of these tumors and compared with the non-targeted cytoxic radical 2-pyrrolinodoxorubicin. Induction of MDR proteins MDR-1, MRP-1 and BCRP of targeted and non-targeted therapy were evaluated by real-time PCR. Growth of human MX-1, MDA-MB-231, MDA-MB-435, MDA-MB-468 and DU-4475 breast cancers were signifcantly inhibited by AN-215. Growth of ES-2, UCI-107 and OV-1063 ovarian cancers was significantly reduced by AN-215. UCI-107 tumors were also signifcantly inhibited by AN-238 or an equimolar mixture of AN-215 and AN-238. Significant tumor inhibition of HEC-1-A, RL-95-2 and AN3CA human endometrial cancers was achieved by targeted therapy with AN-207, AN-215 and AN-238. Tumor inhibition in these models ranged between 40-68%. The cytotoxic radical 2-pyrrolinodoxorubicin alone did not significantly affect tumor growth in any experiment. White blood cell count in nude mice was significantly affected by 2-pyrrolinodoxorubicin, but not by targeted therapy. Low or no induction of MDR-1, MRP-1 and BCRP occurred after targeted therapy with AN-215 and AN-238. Targeted therapy of breast, endometrial and ovarian cancer with cytotoxic peptide analogs AN-207, AN-215 and AN-238 is more effective and less toxic than non-targeted chemotherapy. AN-215 and AN-238 do not induce MDR proteins MDR-1, MRP and BCRP. Targeted therapy with cytotoxic peptide analogs should be a novel and effective treatment approach for gynecological cancers.
A typical hazard: Wallabies on the runway
Authors: T H H G Koh
Journal: BMJ (1999)

1 MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 1991;338:131-7. 2 Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. BMJ 1993;306:1645-9. 3 Report from an Expert Advisory Group (1992) on folic acid and the prevention of neural tube defects. London: Department of Health; Scottish Office Home and Health Department; Welsh Office; Department of Health and Social Services, Northern Ireland, 1992. 4 McGovern E, Moss H, Grewal G, Taylor A, Bjornsson S, Pell J. Factors affecting the use of folic acid supplements in pregnant women in Glasgow. Br J Gen Pract 1997;47:635-7.
The effect of cyclooxygenase-2 inhibition on arachidonic acid metabolism in cancer cell lines
Authors: Seokwoo Park, Sun-Hui Shim, Myung-Whun Sung
Journal: Clinical Cancer Research (2007)

B9  The observed over-expression of cyclooxygenase-2 (COX-2) in many types of cancer has highlighted this molecule as a potential target for therapeutic intervention. Also, it has been recently found that 5-lipoxygenase (5-LO) and cytochrome P450-2J2 (CYP2J2), another participants of arachidonic acid (AA) metabolism might have enough action to promote cancer cell viability through several mechanisms similar to those of COX-2. In head and neck squamous cell carcinoma (HNSCC) cell lines, we found that 5-LO is up-regulated as well as COX-2. Although COX-2 was highly expressed in all tested cell lines, several COX-2 inhibitory chemicals at low doses required to block COX-2 activity showed little growth inhibitory effect in our model. From these observations, we considered the possible interaction between COX-2 and 5-LO in AA metabolism to improve anti-cancer effect of COX-2 inhibition. Although low doses of NS-398 (~12.5uM) - COX-2 selective inhibitor and REV5901 (~6.25uM) - 5-LO inhibitor were enough to block synthesis of PGE2 and LTB4, they showed little cell growth inhibition of SNU-1041 individually. However, the combined treatment of NS-398 and REV5901 showed much better anti-cancer effect than any single application of them. We observed that COX-2 inhibition increased LTB4 produced by 5-lipoxygenase in all tested cells. From these findings, we assume that the combined inhibition of COX-2 and 5-LO related to AA metabolism should be necessary to overcome low efficacy of single inhibition of COX-2 and reduce the unexpected side effect by high doses of chemicals than it would be the optional modality in cancer cell with both expression of COX-2 and 5-LO. In another words, observation on expression of other factors related to AA pathway might be needed to optimize treatment efficiency of COX-2 inhibition in any cancer patients.
Abstract 1881: 2D Speckle Track Strain Measurements From High Resolution Dynamic Ultrasound Images Can Provide Clues to Functional Architecture of the Heart
Authors: Muhammad Ashraf, Min Pan, Peter Lysyansky, David J Sahn
Journal: Circulation (2007)

Background: This study evaluated regional and global strain in subendocardial (s-endo) and subepicardial (s-epi) layers of the left ventricular (LV) wall on high frame rate high resolution images f...
Abstract 764: Characterization Of A Novel Receptosome Involved In Signaling, Trafficking And Networking Of The Human Beta-1-adrenergic Receptor
Authors: Suleiman Bahouth, Lidia A Gardner
Journal: Circulation (2007)

The beta1-adrenergic receptor (beta1-AR) mediates many of the cardiovascular actions of catecholamines and its down-regulation is a hallmark of cardiac failure. Persistent activation of the human b...
Expression of prohibitin 1 mitochondrial protein in non-COPD and COPD smokers
Authors: Nikolaos Soulitzis, Eirini Neofytou, Maria Psarrou, Sotiris Menikou, Nikolaos Siafakas, Eleni Tzortzaki
Journal: European Respiratory Journal (2011)

Introduction: Prohibitin 1 (PHB1) is a versatile protein that is located in the inner mitochondrial membrane, maintaining normal mitochondrial function and morphology. Prohibitin interacts with NADH dehydrogenase, a protein complex essential for the oxidoreductase activity within cells. However, its expression in lung epithelium, especially in patients with inflammatory lung diseases associated with increased oxidative stress, such as COPD, is unknown.

Aim: To study PHB1 expression in lung tissue of non-smokers, non-COPD smokers and COPD patients.

Methodology: Lung tissue specimens from 30 male subjects were studied: 15 COPD patients [age: 65.9±6.2 years, smoking: 88.9±35.2 pack-years, FEV1 (% pred): 58.4±16.4, FEV1/FVC (%): 66.2±8.6], 10 non-COPD smokers [age: 57.0±11.7 years, smoking: 67.1±39.9 pack-years, FEV1 (% pred): 84.0±15.9, FEV1/FVC (%): 80.0±3.8] and 5 non-smokers. Quantitative Real-Time PCR and Western Blot experiments were carried out for PHB1, using beta-actin as internal control.

Results: Non-COPD smokers exhibited lower prohibitin levels when compared to non-smokers (0.55±0.06 vs. 0.90±0.06, p=0.011), while PHB1 mRNA levels were even further decreased in COPD patients (0.32±0.02), a finding statistically significant vs. both non-COPD smokers (p=0.012) and non-smokers (p=0.009). Western blot analysis verified the above results (non-smokers: 1.77±0.10; non-COPD smokers: 0.97±0.08; COPD patients: 0.62±0.09, p=0.028).

Conclusion: The significantly downregulated prohibitin levels in non-COPD and COPD smokers in comparison with non-smokers possibly reflects a distorted mitochondrial function, resulting in decreased anti-oxidant activity, especially in the mitochondria of COPD patients.
Abstract 18126: Ectodomain Shedding and Autocleavage of the Cardiac Membrane Protease Corin
Authors: Jingjing Jiang, Wei Wang, Shenghan Chen, Xiumei Zhang, Qingyu Wu
Journal: Circulation (2010)

Corin is a membrane serine protease expressed primarily in the heart, where it regulates blood pressure and cardiac function by activating natriuretic peptides. Recently, soluble corin was detected...
Abstract 2236: Usefulness of 64-Slice Computed Tomography in Patients Undergoing Percutaneous Coronary Intervention of Chronic Total Occlusion
Authors: Alice Ohanessian, Thierry Lefévre, Sanjay Sastry, Yves Louvard, Pierre Dumas, Marie-Claude Morice
Journal: Circulation (2008)

Background. Despite constant technical advances, percutaneous coronary intervention (PCI) of chronic total occlusion (CTO) remains a challenge with procedural success ranging from 65 to 85% in high volume center. MSCT provides information which cannot be obtained with conventional coronary angiography such as: plaque constitution, calcifications and distribution, route and distal run off. A better knowledge of these parameters may influence the approach to such complex PCI, optimize procedural strategy and success. The aim of our study was to evaluate the usefulness of cardiac CT before PCI of CTO. Methods . All patients with CTO underwent 64-slice CT before the scheduled PCI. We used a scan protocol with 64±0.625mm slice collimation (pitch 0.2), 350 ms (General Electric Lihgtspeed VCT) and 420 ms (Philips Brillance) rotation time and simultaneous (ECG) gating. Patients with heart rates above 65 bpm received intravenous beta-blockade. All CT examinations were performed with retrospective electrocardiogram gating. Exclusion criteria were atrial fibrillation and creatinemia &gt;140 μmol/l. Results . Sixty patients were included in the study. Mean age was 63.58.5 yrs, 90% were male. On MSCT, the occlusion length was 25.5mm16.5 (33.119.8 on angiography). Calcifications were evaluated as minimal in 42% (26% angio), moderate in 42% (54%) and severe in 1% (12%) of the cases. No calcification was found in 15% (8%). A possible coronary route was identified in 68% (18% on angio), the lumen was relatively visible in 77%, acceptable in 23% and eccentric in 98%. One side branch was observed in 62 %, two in 8% and none in 30% of the CTO. Procedural difficulty was assessed by angio using a scale of 1 (very easy) to 5 (extremely difficult) with a mean rate of 3.540.92 falling to 2.620.81 after reading the MSCT data. MSCT was deemed as extremely useful in 80%, useful in 18% and non useful in 2%. Overall procedural success was achieved in 79% of the CTOs. Conclusion . MSCT appears to be a new tool for optimising procedural strategy and increasing success rate in CTO angioplasty.
Intervention for Acute Stroke—Reply
Authors: Shyam Prabhakaran, Ilana Ruff, Richard A. Bernstein
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
患者调查显示：候诊时间减少，但医院仍然很脏
Authors: ZosiaKmietowicz, 石朝云
Journal: BMJ (2005)

独立医疗监察员的2项主要调查显示：英格兰的患者在急诊治疗和门诊预约已不像以往那样要等太长时间。但是。患者对医院的卫生状况仍不满意。而且他们想了解更多关于治疗以及处方药可能的副作用的信息。
Assessments should be independent
Authors: F. Finlay, R. Jones
Journal: BMJ (1995)

While screening for medical fitness to drive may seem an attractive idea, it is unrealistic.Not only is there a lack of effective screening tests but recent data suggest that this sort of strategy may be not only ineffective but also harmful.Some European countries have attempted to screen for illness relevant to driving by demanding a doctor's certificate at regular intervals after the age of 70.A comparison of accident rates between Sweden (where there is no medical control) and Finland (where regular medical recertification is required after age 70) showed no reduction in fatalities in motor crashes and an increase in pedestrian and cycle fatalities in Finland.This may be a result of stopping older people driving unnecessarily and forcing them into the much higher risk group of pedestrians and cyclists.'
Metastatic renal cell carcinoma tumor growth suppression using adenoviral vectors expressing endostatin-angiostatin fusion protein
Authors: Matthew Mellon, Miwon Ahn, Yan-Ping Zhang, Juan Jimenez, Chinghai Kao, Thomas Gardner
Journal: Cancer Research (2007)

3313   INTRODUCTION AND OBJECTIVE: Renal Cell Carcinoma (RCC) is the third most common urologic neoplasm. Radiation and chemotherapy have largely proven ineffective in treating metastatic disease. Immunotherapy has shown modest results. These limitations have prompted investigation into novel techniques. One promising area is gene therapy. The highly vascular tumors of RCC appear to be highly susceptible to antiangiogenic gene therapy. The aim of this study was to produce metastatic tumor inhibition using combined treatments of tailored adenovirus therapy.  METHODS: Subcutaneous RCC-29 tumors were induced in 7-week old athymic nude male mice by injecting 2x10 6  cells bilaterally into each flank region. On days 2 and 10 post-injection, the mice were subjected to an intratumoral injection of adenoviral vector on the right flank only. The mice were randomly assigned to seven treatment groups: control (n=7), GFP (n=7), Tie2 (n=9), Endostatin/Angiostatin (n=8), GFP + Tie2 (n=7), GFP + EndoAngio (n=9), and EndoAngio + Tie2 (n=8). Each group received two injections of 2x10 9  PFU respectively. The tumor volumes were measured twice weekly for 60 days. Additionally, during days 40-50 of the trial, the subjects were administered fluorescent rhodamine-conjugated BSA dye and skin windows were established over the tumors. Using dual-photon optical imaging, qualitative assessment of tumor vasculature was performed.  RESULTS: Tumors treated with adenovirus expressing endostatin-angiostatin fusion protein, GFP + EndoAngio, and EndoAngio + Tie2 demonstrated 82%, 83%, and 87% growth reduction respectively (p in vivo  imaging illustrated a reduction in blood vessel number and size in the EndoAngio treatment groups as compared to controls.  CONCLUSIONS: These results suggest that adenoviral vectors expressing Endostatin/Angiostatin fusion proteins have effective antiangiogenic action against human RCC cells and possess great potential as a novel treatment for metastatic renal cell carcinoma.
Abstract 4178: Adenosine Induced Stress Myocardial Perfusion Imaging using Dual Source Cardiac CT:Initial Clinical Experience
Authors: Ron Blankstein, Anand V Soni, Ammar Sarwar, Ian Rogers, Leon Shturman, Milena Petranovic, Wilfred S Mamuya, Hiram Bezerra, Khurram Nasir, Ricardo Loureiro, David Okada, Udo Hoffmann, Thomas J Brady, Ricardo C Cury
Journal: Circulation (2008)

Intro : The feasibility and accuracy of performing a comprehensive CT exam incorporating coronary, stress and rest perfusion, and delayed enhancement (DE) imaging is unknown. Our goal was to determine the feasibility of stress DSCT in identifying and quantifying the extent of ischemic and infarcted myocardium as compared to nuclear myocardial perfusion imaging (MPI) and invasive angiography (IA). Methods : 12 consecutive pts who had a prior MPI &amp; subsequently underwent IA were included in study. DSCT (2×32×.6) performed as follows: Stress CT (SCT) - retrospectively gated scan with tube current modulation and pitch adaptation obtained 3 min post adenosine (.14 mg/kg/min) with Isovue @ 4 –5 ml/s; Rest CT (RCT) - non-helical prospective scan, Isovue @ 4 –5 ml/s; DE Scan - prospective acquisition 7 min post RCT, 100kV. CT perfusion, CT angiography (CTA), MPI, and IA were each read blinded to results of other tests. For DSCT &amp; MPI, perfusion defect (pd) severity &amp; reversibility were scored for ea. of the 17 segments. CT interpretation used 10mm multi planar reformation in short axis. Per vessel results of SCT were compared to the following references S-MPI IA≥50% IA≥70% CTA severe stenosis &amp; S-MPI &amp; IA≥50. Results : Protocol was successfully completed for all 12 pts (44±11 yrs; 10 males; BMI 31.5±7 kg/m 2 ) 11/12 pts had prior CAD; 5/12 had a prior MI and 3/12 had a prior PCI. Total contrast dose was 151cc; Average radiation dose of protocol 13mSv (8.8, 2.8, and 1.3mSv for SCT, RCT, and DE respectively). Average HR was 71 for RCT &amp; 80 for SCT. Out of 204 segments (17×12pts), RCT pd were identified in 39 (5tr=transmural), SCT pd in 86 (40tr) and DE in 22 (3tr). S-MPI pd were present in 66 segments. Per vessel analysis: IA&gt;70% lesions in 19/36, SCT identified pd in 25/36 and S-MPI in 21/36. Compared to MPI, SCT had a sensitivity (Sn) of 91% &amp; specificity (Sp) of 43%. When IA&gt;70%, used as the reference the Sn &amp; Sp were: 79 &amp; 41% for SCT, 63 &amp; 47% for S-MPI, 89 &amp; 65% for CTA, and 84 &amp; 71% when abnormal on both CTA &amp; SCT (p=NS). Conclusions : Adenosine stress CT can accurately identify both anatomical stenosis as well as reversible and nonreversible perfusion defects. The role of stress CT is unknown at this time and larger datasets will be necessary for accurate comparison with nuclear MPI.